1)Tanaka M, Castillo CF, Adsay V, et al.International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas.Pancreatology. 2012; 12: 183-97
|
|
|
2)Maguchi H, Tanno S, Mizuno N, et al.Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan.Pancreas. 2011; 40: 364-70
|
|
|
3)Kobayashi G, Fujita N, Maguchi H, et al.Natural history of branch duct intraductal mucinous neoplasm with mural nodules.Pancreas. 2014; 43: 532-8
|
|
|
4)Shimizu Y, Yamaue H, Maguchi H, et al.Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers.Pancreas. 2013; 42: 883-8
|
|
|
5)Kamata K, Kitano M, Kudo M, et al.Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.Endoscopy. 2014; 46: 22-9
|
|
|
6)真口宏介.残された課題-IPMNの経過観察法について-.膵臓.2013; 28: 148-55
|
|
|
7)Vege SS, Ziring B, Jain R, et al.American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.Gastroenterology. 2015; 148: 819-22
|
|
|